About MeMed
MeMed is a company based in Tirat Carmel (Israel) founded in 2009 by Kfir Oved and Eran Eden. MeMed has raised $163 million across 10 funding rounds from investors including OurCrowd, Foxconn Electronics and Social Capital. MeMed offers products and services including MeMed BV and MeMed Key. MeMed operates in a competitive market with competitors including Prenetics, Inflammatix, Visby Medical, GenMark Diagnostics and Molbio Diagnostics, among others.
- Headquarter Tirat Carmel, Israel
- Founders Kfir Oved, Eran Eden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Memeds Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$163 M (USD)
in 10 rounds
-
Latest Funding Round
$93 M (USD), Series D
Jan 10, 2022
-
Investors
OurCrowd
& 21 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MeMed
MeMed offers a comprehensive portfolio of products and services, including MeMed BV and MeMed Key.
15-minute assay to differentiate bacterial and viral infections for better treatment.
Compact device for quick, multiplexed protein measurements in clinical settings.
People of MeMed
Unlock access to complete
Unlock access to complete
Funding Insights of MeMed
MeMed has successfully raised a total of $163M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $93 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MeMed
MeMed has secured backing from 22 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include OurCrowd, Foxconn Electronics and Social Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Horizons Ventures is focused on investing in deep science and technology.
|
Locked | Locked | Locked | |
|
Private equity investments in Israel are managed by Shavit Capital.
|
Locked | Locked | Locked | |
|
US focused VC firm investing in seed & growth stage companies
|
Locked | Locked | Locked |
Investor details for MeMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MeMed
Investment portfolio details for MeMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MeMed
Detailed financials for MeMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Memed Comparisons
Peer comparison for MeMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MeMed
MeMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Inflammatix, Visby Medical, GenMark Diagnostics and Molbio Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
Detailed competitors of MeMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Memed
Complete news archive for MeMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MeMed
MeMed was founded in 2009 and raised its 1st funding round 6 years after it was founded.
MeMed is headquartered in Tirat Carmel, Israel. It is registered at Tirat Carmel, Haifa District, Israel.
Eran Eden is the current CEO of MeMed. They have also founded this company.
MeMed is a funded company, having raised a total of $163M across 10 funding rounds to date.
MeMed Diagnostics provides machine learning-based diagnostic solutions for infectious diseases. The companys lead product ImmunoXpert, distinguishes between bacterial and viral infections based on the patients immune response in-vitro diagnostic test. The company also offers ImmunoPoC, a device for distinguishing between bacterial and viral infections at the point-of-care. The company also provides its immunoassay platform MeMed Key. Its solution also diagnoses infections inaccessible for direct pathogen sampling and avoids false alarms due to the presence of non-pathogenic bacteria and viruses.
MeMed's top competitors include Visby Medical, Inflammatix and Prenetics.
MeMed offers MeMed BV and MeMed Key.
MeMed has 22 investors. Key investors include OurCrowd, Foxconn Electronics, Social Capital, Ping An, and European Commission.